ACRS Nov 2024 1.500 put
| Previous close | 0.6000 |
| Open | 1.3000 |
| Bid | 0.4500 |
| Ask | 0.5500 |
| Strike | 1.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.6000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireAclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through
Simply Wall St.Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
A week ago, Aclaris Therapeutics, Inc. ( NASDAQ:ACRS ) came out with a strong set of first-quarter numbers that could...
Insider MonkeyAclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript May 7, 2024 Aclaris Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23835, expectations were $-0.28. Aclaris Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]
